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HPV-16 virions can remain 
infectious for 2 weeks on senescent 
cells but require cell cycle re-
activation to allow virus entry
Justyna Broniarczyk1,2, Nadja Ring1, Paola Massimi1, Mauro Giacca  1 & Lawrence Banks1
Successful infection with Human Papillomaviruses requires mitosis, when incoming viral genomes 
gain access to nuclear components. However, very little is known about how long HPV particles can 
remain infectious in non-dividing cells or in which cellular compartments these viruses may reside. To 
investigate these questions we have used BJ cells as a reversible model of senescence and show that 
HPV-16 can only infect early-passage proliferating cells. Late-passage senescent cells are resistant to 
HPV infection, but this can be reversed by inducing cell cycle re-entry with a p53 siRNA. In senescent 
cells we find that efficient virus entry can be attained upon cell cycle re-entry 16 days after infection, 
demonstrating that HPV can persist for 2 weeks prior to induction of mitosis. However, exposing cells 
to anti-HPV-16 L1 neutralising antibody blocks infection at these late time points, suggesting that the 
virions reside near the cell surface. Indeed, immunofluorescence analysis shows that virions accumulate 
on the cell surface of senescent cells and only enter endocytic vesicles upon stimulation with p53 siRNA. 
These results demonstrate that HPV-16 virions can remain viable on a non-dividing cell for extended 
periods of time, but are nonetheless vulnerable to antibody-induced neutralisation throughout.
Human Papillomaviruses (HPVs) are major human pathogens and the causative agents of a number of important 
human malignancies, with cervical cancer being the most important1,2. The viruses replicate in differentiating 
epithelia, where the virus initially gains access to the basal cell compartment, which is thought to occur through 
microtraumas in the skin. Once infected, the basal keratinocyte begins to differentiate and the combined action 
of the viral oncoproteins, E6 and E7, promotes cell cycle entry and replication of the viral genomes. Ultimately 
this process results in the production of new infectious virus particles in the upper terminally-differentiated 
layers of the skin3,4. In rare cases this infectious cycle is perturbed, and over a number of years malignancies can 
subsequently arise.
The viral capsid contains the double stranded viral genome of approximately 8 kb, which is enclosed by the 
viral coat proteins L1 and L25,6. Whilst both proteins play essential functions in capsid assembly and virus entry, 
the viral L2 protein appears to be the most important for ensuring delivery of the viral genome to the infected cell 
nucleus, where viral gene expression can initiate7,8. The whole process of virus infection involves multiple steps. 
After the initial attachment of incoming virions to the extracellular matrix9,10, there is a structural alteration to 
the viral capsid, which allows binding to the target cell and subsequent endocytic uptake11,12. During the process 
of endocytic maturation and acidification the capsid begins to disassemble, and at some point in this process the 
L2 proteins become partially exposed to the cytoplasmic side of the endocytic vesicle13,14. This exposure of L2 
plays a critical role in recruiting different components of the endocytic cargo sorting machinery, which includes 
components of the retromer complex15,16 and members of the sorting nexin protein family17,18. Components of 
the ESCRT machinery also seem to play an important role in these early steps of infectious entry19–21 and even-
tually, through the action of cyclophilins, the L1 protein becomes largely dissociated from the L2/DNA complex 
and is processed to the lysosomal compartments and degraded22, whilst the L2/DNA complex is trafficked to the 
trans-Golgi network23. Only upon the initiation of mitosis and nuclear envelope breakdown does the L2/DNA 
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complex, accompanied by a small amount of residual L1, then gain access to the nucleus where the viral genome 
ultimately resides at PML oncogenic domains (PODs)24–26. Viral gene expression is believed to initiate at these 
domains and the onset of a new round of viral genome amplification and viral production proceeds7,8.
This whole entry process is thought to be rather slow, often taking many hours, although if infection occurs 
at a point when the cells are about to divide then entry into the nucleus can be much faster27. Virus uptake itself 
is also believed to be dependent upon growth factor signalling, and there is some evidence to suggest that virus 
entry may in part be linked to growth factor receptor internalisation, suggesting that there is preferential entry of 
the virus into proliferating cells28,29. Nonetheless a critical step in this whole pathway is the initiation of mitosis, 
without which the virus cannot gain access to the nucleus and the infection fails24,25.
Whilst HPV virions are known to be quite resilient, there is very little information on how long they can 
remain infectious once exposed to their target cells, or for how long, or where, such viruses might reside in a 
cell that is not undergoing mitosis. In order to begin to provide some answers to these questions we have made 
use of a model of reversible replicative cellular senescence. BJ cells are fibroblasts that undergo replicative senes-
cence following extended periods of passage in tissue culture, a process first described in 196530. However these 
cells can be stimulated to re-enter the cell cycle and divide further by transfecting them with siRNAs that knock 
down components of the p53 signalling pathway, including p53 itself and p2131. Using this model system we have 
investigated how long virus particles can remain viable once exposed to senescent cells before they are triggered 
to re-enter the cell cycle. We have also ascertained where virions can reside long-term in the cell when the cell is 
outside the cell cycle and before induction of mitosis. To our surprise, we find that under these conditions virions 
can remain infectious for several weeks, not in internal vesicular compartments but instead retained on the cell 
surface in a location accessible to neutralising antibodies.
Materials and Methods
Cell lines and transfections. Human diploid foreskin fibroblasts (BJ, ATCC CRL-2522) were a generous 
gift from Fabrizio D’Adda Di Fagagna’s laboratory and were cultured in MEM with Glutamax supplemented with 
10% fetal bovine serum, penicillin-streptomycin (1%), glutamine (2 mM), non-essential amino acids (10 mM) 
and sodium pyruvate (1 mM). In order to be able to observe viral persistence in non-dividing cells, BJ fibroblasts 
were serially cultured at 37 °C and 95% humidity with 5% CO2 to replicative senescence. At this point, less than 
10% of the cells incorporated EdU over the course of a 24 h period, with the majority of cells displaying a cell cycle 
arrest. Cells were either subcultured (using 0.05% trypsin-EDTA) or submitted to a medium change approxi-
mately every 4 days and kept at a maximum confluence of approximately 90%. HeLa cells were maintained in 
DMEM supplemented with 10% fetal bovine serum, penicillin-streptomycin (1%), glutamine (2 mM).
BJ cells were transfected following a reverse transfection protocol using Lipofectamine RNAiMAX 
(Invitrogen) with siRNAs against p53 (Sigma) or non-targeting siRNA (control siRNA, Dharmacon) as a control. 
In order to monitor transfection efficiencies, an siRNA targeting the ubiquitin complex (siUBC, Dharmacon) was 
used in all assays, which is cytotoxic after successful transfection, and verified transfection efficiencies of over 
90%.
Cell cycle analysis with flow cytometry. 4 × 105 senescent or replicating BJ fibroblasts were plated on 
6 cm dishes. Senescent cells were reverse transfected with control or p53 siRNA to a final concentration of 50 nM. 
Cells were harvested 72 h post-transfection and cell cycle analysis was performed with a fluorescence-activated 
cell sorter (FACS) by measuring DNA content using propidium iodide staining as described previously32.
EdU incorporation assay. 1.5 × 103 senescent BJ cells were reverse transfected in a 384-well plate with 
control siRNA, p53 siRNA and UBC siRNA as a control for cell viability. After 48 h 10 µM EdU was added to the 
cells and after 24 h the cells were fixed and stained with Click-IT (Thermo Fisher Scientific) following the manu-
facturer’s protocol.
Western blot. 1.3 × 105 senescent BJ cells were untreated or reverse transfected in a 6-well plate with control 
siRNA or p53 siRNA and harvested in RIPA buffer after 72 h. Equal amounts of protein were separated using 
SDS-PAGE and transferred to a nitrocellulose membrane. The p53 protein was detected using the anti-p53 (DO-1) 
mouse monoclonal antibody (sc-126, Santa Cruz Biotechnology), and the loading control alpha-actinin was 
detected using the rabbit anti-alpha-actinin (H-300) polyclonal antibody (sc-15335, Santa Cruz Biotechnology). 
Western blots were developed using appropriate secondary antibodies conjugated to HRP followed by ECL 
detection.
PsVs production. Different HPV-PsVs containing a luciferase reporter plasmid were generated in 293TT 
cells as described previously33. Purity and capsid protein content were determined by SDS-PAGE and Coomassie 
Brilliant blue staining, while the encapsidated DNA was quantified using Real-Time PCR and the copy number 
was calculated using a standard curve of reporter plasmid DNA. AF488-labelled PsVs were prepared using the 
Alexa Fluor 488 Protein labelling kit (Molecular Probes).
Infectivity assay. BJ senescent cells were seeded in 96-well plates at a density of 4 × 103 cells per well, and 
exposed to 100 vge/cell of luciferase reporter positive PsVs. 1, 13 or 27 days post-infection (with cells subjected 
to several medium changes), cell division was activated by transfection with p53 siRNA and harvested 72 h later 
(constituting 4, 16 or 30 days post-infection). Infection was monitored by luminometric analysis of firefly lucif-
erase activity using the Luciferase Assay System (Promega). For each assay, PsVs infection in the presence of 
control siRNA was normalized to 100%, which was then used to calculate the percentage increase following 
transfection of the cells with the p53 siRNA.
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To compare HPV-16 PsVs infectivity in different cell lines, BJ early passage cells and HeLa cells were seeded 
in a 96-well plate at a density of 2.5 × 103 cells per well, and exposed to 100 vge/cell of luciferase reporter-positive 
PsVs. Two days post-infection cells were lysed and analysed for luminescence as an indication of efficient infec-
tion. Throughout, equal amounts of total cell protein extract were used in the luciferase measurements.
Transferrin uptake. For analysis of transferrin internalisation, senescent cells were reverse transfected with 
control siRNA and p53 siRNA and plated on 0.01% poly-L-lysine-coated LabTek 8-well chamber slides (Thermo 
Fisher Scientific) at a density of 1.4 × 104 cells per well. 72 h after transfection cells were incubated for 30 min at 
37 °C in serum-free MEM Glutamax with addition of 50 µg/ml AF647 labelled transferrin (Molecular Probes). 
Following incubation, cells were washed several times with PBS and fixed in 3.7% paraformaldehyde (PFA) for 
15 min for fluorescence microscopy analysis. Cells were incubated for 1 h at room temperature with 10% goat 
serum and later EEA1 detection was performed using rabbit anti-EEA1 (C45B10, Cell Signaling Technology) 
and secondary goat anti-rabbit AF546-conjugated antibody (Molecular Probes). Slides were visualised using a 
Zeiss Axiovert 100 M microscope attached to an LSM 510 confocal unit. Transferrin uptake was analysed using 
ImageJ. 15 fields acquired with a confocal microscope were analysed per condition, with over 130 cells in total 
analysed for both control and treated samples. The mean intensity of the transferrin staining was measured for 
each individual cell, disregarding the cell area. A second analysis was performed whereby the integrated intensity 
(the product of mean intensity and cell area) was used to represent the total transferrin content of each cell.
Immunofluorescence. BJ senescent cells were reverse transfected with control siRNA and p53 siRNA 
and seeded on LabTek 8-well chambers slides (Thermo Fisher Scientific) at a density of 1.4 × 104 cells per well. 
One day after, the cells were exposed to 500 vge/cell of AF488-labelled PsVs. 48 h after infection and 72 h after 
transfection, cells were fixed in 3.7% paraformaldehyde for 15 min, incubated for 1 h with 10% goat serum and 
then stained using antibodies for early endosomes (rabbit anti-EEA1, C45B10, Cell Signaling Technology) and 
lysosomal markers (mouse anti-LAMP1, D4O1S, Cell Signaling Technology). Donkey anti-rabbit 594 and goat 
anti-mouse rhodamine were used as secondary antibodies (Molecular Probes). Slides were visualised using a 
Zeiss Axiovert 100 M microscope attached to an LSM 510 confocal unit.
Neutralisation assay. Neutralisation assays were performed using the anti-L1 neutralising antibody (H16.
V5), which was kindly provided by Neil Christensen34. In infectivity assays neutralising antibody was added to the 
medium (dilution of 1:1000) 24 h prior to adding siRNA, and infectivity was measured at 16 days post-infection 
as described above. In immunofluorescence assays cells were transfected and 1 day later cells were infected, and 
2 days post-transfection the anti-L1 neutralising antibody was added to the medium at a dilution of 1:200. Cells 
were fixed 3 days post-transfection and neutralising antibody was visualised using secondary goat anti-mouse 
rhodamine antibody (Molecular Probes).
Statistics. All experiments were performed at least in triplicate, and data are shown as mean and standard 
deviation. Statistical significance was calculated using the GraphPad prism 6 software. To compare two groups 
the Student’s t-test was performed, to compare several samples a 1-way ANOVA calculation was followed by 
Dunnett’s multiple comparison test. A p-value below 0.05 was considered statistically significant and throughout 
the p-values have been defined as follows *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, while “ns” repre-
sents a non-significant p-value above 0.05.
Results
Previous studies have shown that completion of mitosis is an absolute requirement for allowing completion of 
HPV-16 infectious entry24,25. However we have been interested in understanding where incoming virions reside 
until the onset of mitosis and for how long such virions can remain viable. In order to address these questions we 
made use of a well-established model of cellular senescence. In the BJ cell model, early passage cells grow rapidly, 
but following extensive periods of passage they enter senescence. This is indeed confirmed in Fig. 1a, where it can 
be seen that late passage cells show very low levels of DNA replication. However, transfection of a p53 siRNA, the 
efficacy of which was verified by Western blotting in Fig. 1b, efficiently reverses the senescent phenotype, and as 
can be seen from the EdU incorporation assay in Fig. 1c and d these cells re-enter the cell cycle and activate DNA 
replication.
Using this model system, we first compared the ability of HPV-16 PsVs carrying a luciferase reporter construct 
to infect early passage BJ fibroblasts cells and cervical tumour-derived HeLa cells. The results in Fig. 2a show that 
the BJ fibroblasts are susceptible to infection with the HPV-16 PsVs, although somewhat less so than HeLa cells. 
Having found that BJ fibroblasts can be used in such infection assays, we next compared the ability of HPV-16 
PsVs carrying a luciferase reporter gene to infect early and late passage BJ cells. As can be seen from Fig. 2b, early 
passage BJ cells are efficiently transduced using the HPV-16 PsVs but the late passage senescent cells are not, 
which is consistent with their not undergoing cell division. These assays were then repeated in the presence of 
p53 siRNA, and as can be seen from Fig. 2c, this renders the late passage cells susceptible to HPV-16 infection 
and promotes transduction of the reporter construct, consistent with reactivation of cell division, allowing the 
incoming viruses to gain access to the nucleus during mitosis.
We were next interested in investigating how long the virus can survive post-infection before transfection of 
the p53 siRNA. To do this, late passage BJ cells were exposed to HPV-16 PsVs, and after 24 h the cells were washed 
and medium replaced. The cells were then cultured for 13 days and 27 days, after which they were transfected with 
the p53 siRNA to promote cell cycle re-entry. HPV-16 infectious entry was then measured 48 h later by extracting 
the cells and measuring luciferase activity. It can be seen from Fig. 3a that transfection of p53 siRNA into senes-
cent cells can stimulate transduction of HPV-16 PsVs 16 days after exposure to the virus. However, if the cells are 
exposed 27 days prior to transfection of the p53 siRNA, then no PsV transduction occurs (Fig. 3b). This indicates 
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that wherever the incoming HPV-16 PsVs reside for these extended periods of time in the senescent cells, they 
can remain viable and capable of transducing the reporter construct upon stimulation of cell cycle re-entry for at 
least 2 weeks, but most likely for no longer than 4 weeks. This suggests that in a normal virus infection cells need 
not be immediately proliferating to still be susceptible to virus infection, and that quite extended periods of time 
might pass before proliferation and mitosis commences.
In order to determine where HPV-16 PsVs might reside for such extended periods of time we first analysed 
whether the virus was susceptible to antibody-induced neutralisation. To do this, late passage cells were exposed 
to PsVs as before, and left for a total of 16 days. The anti-L1 neutralising antibody (H16.V5) was added to the cells 
at 12 days post-infection, and at 13 days post-infection cells were transfected with the p53 siRNA. As can also be 
seen from Fig. 3, HPV-16 PsVs are readily neutralised by addition of the anti-L1 antibody, even after exposing the 
cells to virus 12 days earlier. These results demonstrate that the virus is most likely residing on, or very close to the 
cell surface, in a compartment that can be accessed by the anti-L1 antibody. We were then interested in investigat-
ing whether a panel of other HPV types could similarly infect senescent cells when they are stimulated back into 
the cell cycle following transfection of a p53 siRNA. To do this, late passage BJ cells were infected with HPV-2, 
Figure 1. p53 siRNA induces senescent BJ cells to re-enter the cell cycle and re-commence proliferation. 
(a) Flow cytometry analysis of BJ fibroblast cell cycle. Early passage untreated BJ fibroblasts and late passage 
(senescent) BJ fibroblasts (untreated, or transfected with control siRNA or p53 siRNA) were harvested after 72 h 
and the cell cycle was analysed using propidium iodide incorporation. Note that senescent cells are arrested 
in G0 and appear to re-enter the cell cycle following transfection with si-p53. (b) Western blot showing p53 
expression in senescent BJ cells. Late passage (senescent) BJ fibroblasts (untreated, or transfected with control 
siRNA or p53 siRNA) were harvested after 72 h and protein analysis was performed. Alpha-actinin was used 
as a loading control. Note that the levels of p53 in senescent fibroblasts are efficiently reduced by the siRNA 
transfection. (c) Cell proliferation analysis using an EdU incorporation assay. Early and late passage (senescent) 
fibroblasts were plated (untreated or reverse transfected with control siRNA, p53 siRNA or siRNA targeting 
Ubiquitin C (si-UBC)). EdU was added to cells 48 h after transfection, cells were labeled for 24 h and then 
fixed. The incorporated EdU was stained with Click-IT (green), with cell nuclei counter-stained with Hoechst 
33342 (blue). (d) Quantification of EdU incorporation. Plates were acquired using the Image Xpress micro 
microscope (Molecular Devices) and analysed using MetaXpress version 5.3.0.5 to determine percentage of 
EdU incorporation. The results are expressed as the mean of three independent experiments, and the standard 
deviations are shown. Note that cells treated with p53 siRNA (si-p53) have a higher proliferative ability than 
cells transfected with control siRNA.
www.nature.com/scientificreports/
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HPV-5, HPV-16, HPV-18 and HPV-31 PsVs in the presence or absence of p53 siRNA. After 72 h the cells were 
harvested and luciferase activity measured. The results in Fig. 4 demonstrate a similar stimulation of luciferase 
transduction with all HPV types tested following transfection of p53 siRNA, indicating similar requirements for 
infectious entry amongst these different HPV types.
Obviously an important concern from these analyses was whether or not the senescent cells were still undergo-
ing endocytosis. In order to monitor this we analysed transferrin uptake in senescent cells and in cells transfected 
with p53 siRNA. At 72 h post-transfection cells were incubated with AF647-labelled transferrin for 30 minutes 
before cell fixation, and then stained for the early endosomal marker EEA1. As can be seen from Fig. 5, there is 
no major change in endocytic uptake of transferrin in the p53 siRNA-transfected senescent cells, indicating that 
lack of virus uptake is not due to the simple shutting down of endocytic transport pathways. This is supported by 
the quantifications from multiple assays when looking at the average transferrin intensity per cell, but also when 
integrating transferrin intensity, where the average intensity of transferrin is multiplied by the cell area.
Having found that the HPV-16 PsVs remained antibody-neutralisable for an extended period post-infection in 
the senescent cells, we then proceeded to investigate in more detail where such virions might reside prior to cell cycle 
re-entry. We first performed a series of analyses using Alexa Fluor-labelled (AF488) HPV-16 PsVs, where cells were 
first reverse transfected with the siRNAs, infected after 24 h and fixed 48 h post-infection. Cells were then stained 
for the endosomal marker EEA1 and the lysosomal marker LAMP1. The results in Fig. 6 demonstrate no extensive 
co-localisation between the AF488-labelled virus and either EEA1 or LAMP1 in the senescent cells, consistent with 
the virus not entering these cells. Indeed, in many cases the virus appears to accumulate at the cell periphery. In con-
trast, in cells transfected with the p53 siRNA there is clear evidence of virus co-localisation with EEA1 and LAMP1, 
demonstrating that stimulation of cell cycle re-entry also stimulates endocytic uptake of the HPV-16 PsVs.
Figure 2. HPV-16 PsV infection of senescent cells is restored following transfection of p53 siRNA. (a) 
Infectivity assay in early passage BJ and HeLa cells. Early passage untreated BJ fibroblasts and Hela cells 
were infected with HPV-16 PsVs. Two days post-infection cells were lysed and analysed for luminescence 
as an indication of efficient infection. The results are expressed as the means from at least three independent 
experiments, and the standard deviations are shown. (b) Infectivity assay in untreated early and late passage BJ 
cells. Early passage and late passage (senescent) untreated BJ cells were infected with HPV-16 PsVs carrying 
a luciferase reporter plasmid. Four days post infection cells were lysed and analysed for luminescence as 
an indication of efficient infection. The results are expressed as the means from at least three independent 
experiments, and the standard deviations are shown. Note that only early passage untreated BJ cells are 
efficiently transduced using the HPV-16 PsVs, while untreated late passage (senescent) cells are not. (c) 
Infectivity assay in transfected late passage BJ cells. Senescent BJ fibroblasts were infected with HPV-16 PsVs 
carrying a luciferase reporter plasmid and 24 h later transfected with control siRNA, or p53 siRNA. Four days 
post-infection cells were lysed and analysed for luminescence as an indication of efficient infection. The results 
are expressed as the mean of at least three independent experiments, and the standard deviations are shown. 
Note that late passage (senescent) cells are only efficiently transduced if stimulated to re-enter the cell cycle 
through p53 siRNA transfection.
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The above results indicate that HPV-16 PsVs most probably reside on the surface of the senescent cells, and are 
only endocytosed once the cells are stimulated to re-enter the cell cycle following the transfection of the p53 siRNA. 
We then wanted to investigate whether we could visualise the anti-L1 neutralising antibody (H16.V5) co-localising 
with the surface-bound HPV-16 PsVs in the senescent cells. To do this, the cells were transfected with control or 
p53 siRNA and after 24 h infected with AF488-labelled virus; after an additional 24 h the medium was changed and 
non-fixed, non-permeabilised cells were incubated with the anti-L1 antibody. Finally, one day later, the cells were 
washed and fixed and the anti-L1 neutralising antibody was detected by staining with rhodamine-conjugated goat 
anti-mouse antibody. As can be seen from Fig. 7a, the anti-L1 neutralising antibody binds to the surface of unin-
fected BJ cells, and this pattern does not change significantly following transfection of the p53 siRNA. This indi-
cates that these antibodies can bind to the surface of these senescent cells probably through Fc receptors on the cell 
surface. However, in cells that have been infected with the HPV-16 PsVs and transfected with the control siRNA 
(Fig. 7b) it is quite clear that the AF488-labelled HPV-16 PsVs are located mostly on the cell surface, and there is 
clear co-localisation in many cases with the anti-L1 neutralising antibody. These results thus confirm that HPV-16 
PsVs in the non-dividing cells are readily accessible to the neutralising antibody owing to the virus accumulating at 
a surface-exposed location. In contrast, in cells transfected with the p53 siRNA, the bulk of the HPV-16 PsVs have 
entered the cells while the anti-L1 antibody is still present on the cell surface. Under these conditions there is very 
little co-localisation between the AF488-labelled HPV-16 PsVs and the anti-L1 antibody. These results demon-
strate that in non-dividing senescent cells HPV-16 PsVs remain bound to the cell surface, in a location accessible 
to neutralising antibodies. However, following stimulation of cell cycle re-entry there is rapid internalisation of the 
HPV-16 PsVs which are then no longer accessible to the anti-L1 antibody.
Figure 3. HPV-16 PsVs are susceptible to antibody neutralization for 2 weeks on senescent cells. (a) Infectivity 
assay at 16 days post-infection. Senescent BJ cells were infected with HPV-16 PsVs containing the luciferase 
reporter gene. After 13 days, cell division was activated by transfection with p53 siRNA. Cells were harvested 
72 h after transfection and luciferase activity was measured to assess the levels of infection. Additionally, the 
day before adding the siRNA the cells were incubated in the presence or absence of the H16.V5 neutralising 
antibody (1:200). The results are expressed as the means from at least three independent experiments, and 
the standard deviations are shown. (b) Infectivity assay at 30 days post-infection. Senescent BJ cells were 
infected with HPV-16 PsVs containing the luciferase reporter gene. After 27 days cell division was activated by 
transfection with p53 siRNA. Cells were harvested 72 h after transfection and luciferase activity was measured 
to assess the levels of infection. Note that the virus can survive on the cell for 2 weeks, but not 30 days, waiting 
for the initiation of mitosis to allow its entry into the nucleus. The neutralising antibody can block this infection, 
showing that the virus is localised in a position that is accessible to the neutralising antibody.
Figure 4. Comparison of the transduction efficiencies of different HPV types in siRNA p53 transfected 
senescent BJ fibroblasts. Senescent BJ fibroblasts were infected with HPV-2, HPV-5, HPV-16, HPV-18 and 
HPV-31 PsVs carrying a luciferase reporter plasmid and 24 h later transfected with control siRNA, or p53 
siRNA. Four days post-infection the cells were lysed and luciferase activity measured. The results are expressed 
as the mean of at least three independent experiments, and the standard deviations are shown.
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Discussion
HPV infectious entry involves a complex series of steps, which includes interaction with extracellular matrix, 
structural remodelling of the virion, and receptor attachment, followed by endocytosis and the recruitment of 
different components of the cellular transport machinery to ensure delivery of the incoming viral genomes to the 
trans-Golgi network35. Upon entry into mitosis, the nuclear envelope is lost and the viral L2/DNA complex gains 
access to the nucleus where it resides in PODs and where initiation of viral gene expression then takes place7,8. 
The success of this entry process is thus intimately linked to the onset of mitosis24,25. Some major questions arise 
from those studies. In particular, how long can the incoming HPVs remain viable within the infected cell prior 
to the onset of mitosis and where do they reside during this period? Here we have attempted to provide some 
insights into these questions. Using a well-established model of reversible cell senescence31, we have been able to 
show that incoming HPV-16 PsVs can remain viable for up to 13 days post-exposure to the target cells, and can 
efficiently transduce cells after such a period of time if the cells are stimulated to re-enter the cell cycle. To our 
surprise however, we find that these viruses are still sensitive to neutralisation by an anti-L1 neutralising antibody, 
indicating that the virus is located on or near the cell surface during the whole of this period and is not retained in 
an intracellular vesicular compartment. These results obviously have major implications for our understanding of 
how long viruses can remain viable without the target cell entering mitosis, but nonetheless still being accessible 
to antibody neutralisation.
Using the BJ model of replicative senescence we could first confirm previous studies showing that these cells 
gradually cease to proliferate following extended periods in tissue culture. However, cell cycle re-entry can be effi-
ciently induced in these senescent cells following transfection of a p53 siRNA. Using this model we first compared 
the ability of HPV-16 PsVs to transduce a luciferase reporter construct into early passage (proliferating) and late 
passage (senescent) BJ cells. Not surprisingly, we found very good levels of transduction in the early passage cells, 
confirming that many different cell types, including fibroblasts, are susceptible to infection with HPV PsVs36,37. 
In addition, we also confirmed earlier studies demonstrating an absolute requirement for cell proliferation for 
the infectious entry to be successful, with only very low levels of reporter gene transduction being obtained in 
the senescent cell population. However, the efficacy of the model was demonstrated following transfection of the 
senescent cells with a p53 siRNA; this induced cell cycle re-entry and rendered the cells susceptible to infection 
with the HPV-16 PsVs.
Using this model of inducible cell cycle re-entry, we first investigated how long HPV-16 PsVs could remain 
infectious after being exposed to the cells, but prior to the cells undergoing mitosis. We found that virions were 
Figure 5. Transferrin uptake in senescent cells is not improved by re-stimulating cell cycle entry. Senescent 
BJ cells were transfected with control siRNA and p53 siRNA. 72 h post-transfection cells were incubated 
with AF647-labelled transferrin for 30 minutes before cell fixation. Transferrin (blue) co-localises with 
early endosomes EEA1 (red) 30 minutes after its uptake. Representative images are shown in panel (a) and 
quantification of transferrin uptake is shown in panel (b), calculated as average intensity and integrated 
intensity (representing total amount). Note that transferrin uptake and distribution is similar in senescent 
(control siRNA) and proliferating cells (si-p53), with no statistically significant differences in uptake regardless 
of analysis method.
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remarkably stable in these assays, and could readily attain complete infectious entry, as determined by luciferase 
transduction, for up to 16 days post-infection. However, by 30 days, no sign of infectivity remained, indicating 
that virions can remain infectious on a target cell for 2 weeks before the cell enters the cell division cycle and 
completes mitosis. It should be emphasised that the ability of the HPV-16 PsVs to infect these cells is not due to 
the residual presence of free virus in the medium, as we were never able to obtain infectious virus from the tissue 
culture supernatants; rather it indicates the presence of virus either strongly bound or internalised in the target 
cells (data not shown). At this stage we do not know the fate of the virus between the 16- and 30-day time points, 
as we have been unable to recover infectious virus from these cells. Future studies will be required to investigate 
this aspect further.
Obviously, a major question arising from this analysis was; where within the cell does the virus reside whilst 
the cell is in a senescent state for these extended periods of time? We provide strong evidence that under these 
circumstances, HPV-16 PsVs do not actually enter an internal vesicular compartment, but remain attached to the 
cell surface. Several lines of evidence support this conclusion. Firstly in all assays, we found that anti-L1 neutral-
ising antibody could very effectively abolish virus infection, even in cultures where the cells had been exposed 
to virions nearly two weeks prior to neutralisation. Secondly, immunofluorescence analyses failed to show any 
co-localisation of HPV-16 PsVs with either endosomes or lysosomes in senescent cells, and such co-localisation 
was only observed following transfection of the cells with p53 siRNA to promote cell cycle re-entry. Indeed, in 
the senescent cells there was consistent indication of AF488-labelled HPV-16 PsVs accumulating on the cell 
surface. In agreement with this, we found that when non-fixed non-permeabilised cells were exposed to the 
anti-L1 neutralising antibody, this could co-localise with cell-surface-bound HPV-16 PsVs in the senescent cells. 
However when the same assay was performed on cells that had been stimulated to enter the cell cycle, following 
transfection of the p53 siRNA, there was strongly reduced co-localisation of the AF488-labelled PsVs and the 
anti-L1 neutralising antibody.
An important point arising from these studies was whether the senescent cells were simply defective in endo-
cytic uptake. However in an extensive series of assays looking at transferrin uptake, we observed no major differ-
ences between the senescent cells and those that were stimulated back into cell cycle following transfection of p53 
siRNA. Obviously, these studies have the caveat of being performed in fibroblasts and not in basal keratinocytes, 
the natural target cell for these viruses. Indeed, when comparing infectivity of early passage BJ fibroblasts with 
HeLa cells we do indeed see significantly lower levels of infectivity in the fibroblasts. Unfortunately we have not 
been able to identify conditions whereby keratinocytes can be maintained in a growth-arrested state for several 
weeks, making it impossible to perform similar studies in that cell setting. However, these studies nonetheless 
demonstrate an intriguing capacity of the virus to remain viable on the surface of senescent cells for extended 
periods of time, and it is reasonable to speculate that this is also relevant for HPV PsV interactions with other cell 
types.
Figure 6. HPV-16 PsVs trafficking to early and late endosomes is affected in senescent cells. Senescent BJ cells 
were transfected with control siRNA and p53 siRNA. One day after transfection, cells were exposed to Alexa 
Fluor 488-labelled HPV-16 PsVs (green) for 48 h then fixed and stained for endogenous EEA-1 using rabbit 
antibody against EEA-1 and detected using Alexa Fluor 594-conjugated donkey anti-rabbit antibody (red) 
(a) and for endogenous LAMP1 using mouse antibody against LAMP1 and detected using rhodamine red-
conjugated goat anti-mouse antibody (red) (b). Shown are two representative merged images for each condition. 
Note that in senescent cells (control) the virus is mainly localised on the surface of the cells and shows very little 
co-localisation with early endosomes (a) and late endosomes (b) in comparison with proliferating cells (si-p53).
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Figure 7. HPV-16 PsVs in senescent cells are accessible to neutralising antibody. (a) Anti-L1 (H16.V5) 
neutralising antibody binds to the surface of senescent and proliferating cells. Senescent BJ cells were 
transfected with control siRNA and p53 siRNA. 48 h after transfection cells were incubated with anti-L1 
neutralising antibody for 24 h. Then cells were fixed and neutralising antibody was detected with goat 
anti-mouse rhodamine antibody (red) and rabbit antibody against EEA-1, and detected using Alexa Fluor 
647-conjugated donkey anti-rabbit (blue). Two examples are shown for each condition. (b) In infected senescent 
cells the H16.V5 neutralising antibody co-localises with the virus on the surface of cells. One day after siRNA 
transfection, AF488-labelled HPV-16 PsVs (green) were added to the cells. 24 h after infection cells were 
incubated overnight with neutralising H16.V5 antibody, fixed and stained as above. Note that in senescent cells 
transfected with the control siRNA, H16.V5 neutralising antibody co-localises with the virus on the cell surface 
(indicated by arrows). In cells that were transfected with the p53 siRNA there is very little co-localisation 
between the virus and neutralising antibody and virus is visible within the cells, as indicated by the arrows, 
suggesting that virus entry is stimulated post–transfection of the p53 siRNA.
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Taken together, these results have a number of important implications. They once again highlight the impor-
tance of mitosis for completion of virus infection, but they also make a further compelling case that active 
growth-promoting signalling is required for virus uptake to actually take place. Previous studies have indicated 
that EGFR signalling was most likely required for virion uptake, and certainly blocking EGFR with an inhibi-
tory antibody blocks virus entry, suggesting its possible use as an entry receptor28,29. Our studies do not exclude 
this possibility, but they strongly suggest that the proliferative signals associated with the onset of cell division 
are linked to the form of endocytic transport required by HPV for a successful virus infection. Which signalling 
pathways, or types of endocytic transport, are so linked to the cell cycle and virus entry will be a subject of future 
study. Finally these studies also highlight that HPV-16 PsVs are remarkably stable when bound to their target cell, 
and can remain infectious for several weeks. Nonetheless during the whole of this time the virus is highly vulner-
able to neutralising antibodies. This suggests that, from a virological perspective, residing in an internal vesicular 
compartment for extended periods of time is not compatible with virus survival, but rather, being bound to the cell 
surface and primed to enter the cell upon the receipt of appropriate growth-promoting signals is most favourable.
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